JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

Home・Akcijų sąrašas・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

40.96 -2.17

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

40.64

Max

42.05

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-6.2M -91M
Pelno marža	-867.293
Darbuotojai	316
EBITDA	4M -90M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+30.49% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-02-26

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-27M 3.2B
Ankstesnė atidarymo kaina	43.13
Ankstesnė uždarymo kaina	40.96

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

34.81 / 38.24 Palaikymas ir pasipriešinimas

Xenon Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-04 22:55; UTC

Uždarbis

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook -- Update

2026-02-04 21:44; UTC

Uždarbis

Arm Holdings 3Q Profit Falls Despite Revenue Growth

2026-02-04 21:39; UTC

Uždarbis

Qualcomm 1Q Sales Rise, But Memory Shortage Dents Outlook

2026-02-04 23:46; UTC

Uždarbis

Arm Holdings Expects Slower Revenue Growth in 4Q -- Update

2026-02-04 23:46; UTC

Rinkos pokalbiai

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

2026-02-04 23:45; UTC

Karštos akcijos

Stocks to Watch: Crown Castle, Qualcomm, Arm, U-Haul

2026-02-04 23:45; UTC

Uždarbis

Google to Double Spending as Earnings Beat Wall Street Expectations -- 4th Update

2026-02-04 23:32; UTC

Rinkos pokalbiai

Gold Rises on Possible Dip-Buying Amid Lingering U.S.-Iran Tensions -- Market Talk

2026-02-04 22:59; UTC

Įsigijimai, susijungimai, perėmimai

SiTime to Buy Timing Business From Renesas Electronics For $1.5B

2026-02-04 22:30; UTC

Uždarbis

Salesforce Stock Is Battered, and Super Cheap. Hang Tight. -- Barrons.com

2026-02-04 22:30; UTC

Uždarbis

Alphabet's Cloud Is Shining as CapEx Heads Even Higher -- Barrons.com

2026-02-04 22:21; UTC

Uždarbis

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

2026-02-04 22:17; UTC

Rinkos pokalbiai

WiseTech Faces Risks in Both Directions From DSV's Progress -- Market Talk

2026-02-04 22:15; UTC

Rinkos pokalbiai

Santos Should Lay Out Strategic Plans at Annual Result -- Market Talk

2026-02-04 22:00; UTC

Rinkos pokalbiai

ESG Roundup: Market Talk

2026-02-04 21:53; UTC

Uždarbis

Google to Double Spending as Earnings Beat Wall Street Expectations -- 3rd Update

2026-02-04 21:51; UTC

Uždarbis

Snap Stock Pops After Surprise Earnings Beat -- Barrons.com

2026-02-04 21:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-02-04 21:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2026-02-04 21:50; UTC

Rinkos pokalbiai

Uždarbis

Auto & Transport Roundup: Market Talk

2026-02-04 21:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-02-04 21:45; UTC

Uždarbis

Arm Holdings Reported Record Revenue. The Stock is Falling. -- Barrons.com

2026-02-04 21:44; UTC

Uždarbis

Qualcomm Gives Weak Guidance. The CEO Blames Memory Crunch. -- Barrons.com

2026-02-04 21:43; UTC

Uždarbis

Google to Double Spending as Earnings Beat Wall Street Expectations -- 2nd Update

2026-02-04 21:41; UTC

Uždarbis

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

2026-02-04 21:36; UTC

Rinkos pokalbiai

Latest Canada Green Bond Raises C$2 Billion -- Market Talk

2026-02-04 21:30; UTC

Uždarbis

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

2026-02-04 21:30; UTC

Uždarbis

Alphabet Reports Solid Earnings. CapEx Heads Even Higher. -- Barrons.com

2026-02-04 21:30; UTC

Uždarbis

Beach Energy Interim Dividend 1 Australian Cent/Sjare

2026-02-04 21:30; UTC

Uždarbis

Steris Sees FY Adj EPS $10.15-Adj EPS $10.30 >STE

Akcijų palyginimas

Kainos pokytis

Xenon Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

30.49% į viršų

12 mėnesių prognozė

Vidutinis 54.09 USD 30.49%

Aukščiausias 62 USD

Žemiausias 44 USD

Remiantis 13 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Xenon Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

13 ratings

Pirkti

Laikyti

Parduoti

Remiantis 13 analitikų, pateikusių Xenon Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

34.81 / 38.24Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.